| Literature DB >> 28666436 |
Noraisyah Zulkawi1, Kam Heng Ng1, Rizi Zamberi2,3, Swee Keong Yeap4, Dilan Satharasinghe5, Indu Bala Jaganath3, Anisah Binti Jamaluddin3, Sheau Wei Tan2, Wan Yong Ho6, Noorjahan Banu Alitheen2,7, Kamariah Long8.
Abstract
BACKGROUND: Xeniji, produced by fermenting various types of foods with lactic acid bacteria and yeast, has been commonly consumed as functional food. However, nutrition value, bioactivities and safety of different fermented products maybe varies.Entities:
Keywords: Antioxidant; Lactic acid bacteria; Organic acid; T cells; Yeast
Mesh:
Substances:
Year: 2017 PMID: 28666436 PMCID: PMC5493119 DOI: 10.1186/s12906-017-1845-6
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Materials of fermented fruits and vegetables, Xeniji™
| Material name | Content | |
|---|---|---|
| Sugar | Brown sugar, Galacto-oligosaccharide (GOS) and Oligosaccharide | 67.2% |
| Fruits |
| 18.0% |
| Vegetables and wild herbs |
| 7.4% |
| Mushrooms |
| 1.3% |
| Seaweed |
| 1.6% |
| Pulse and Cereals |
| 4.4% |
| Lactic acid bacteria species |
| 0.1% |
Retention time, concentration ranges of lineal response and correlation coefficient for standard organic acids
| Organic acid standard | Rt (min) | Concentration ranges (ppm) | Equation | R2 |
|---|---|---|---|---|
| Oxalic | 3.884 | 1750–350 | Y = 7585.1×-72,810 | 0.9937 |
| Tartaric | 4.148 | 5000–1000 | Y = 2914.9×-2758 | 0.9942 |
| Ascorbic | 5.295 | 1750–350 | Y = 8327.7×-7497.5 | 0.9921 |
| Lactic | 5.857 | 15,000–3000 | Y = 769.58× + 4607 | 0.9939 |
| Acetic | 6.334 | 10,000–2000 | Y = 253.82× + 2571 | 0.9991 |
| Citric | 6.953 | 10,000–2000 | Y = 405.19× + 1826.9 | 0.9953 |
| Succinic | 9.052 | 10,000–2000 | Y = 428.23× + 321.26 | 0.9936 |
| Kojic | 11.31 | 500–100 | Y = 56,358×-22,343 | 0.9913 |
Primer sequences for qRT-PCR gene expression study
| Gene | Primer sequence (5′–3′) | |
|---|---|---|
| Forward | Reverse | |
| GCLM | AATCAGCCCCGATTTAGTCAGG | CCAGCTGTGCAACTCCAAGGAC |
| GSTA2 | CGCCACCAAATATGACCTCT | CCTGTTGCCCACAAGGTAGT |
| IL-2 | TGAGTCAGCAACTGTGGTGG | GCCCTTGGGGCTTACAAAAAG |
| IL-18 | GGGCACCCTAGCTCATGTTT | GCACAAGACGTGTGAGGAGA |
| β-actin | TCCTTCCTGGGCATGGAG | AGGAGGAGCAATGATCTTGATCTT |
Antioxidant, organic acids and amino acids profiles of Xeniji
| Xeniji water extract | ||
|---|---|---|
| Antioxidant profile | Total phenolic content (TPC) | 5.12 ± 0.02 |
| (mg GAE/g extract) | ||
| Total flavonoid content (TFC) | 1.18 ± 0.01 | |
| (mg QE/g extract) | ||
| FRAP | 3.30 ± 0.01 | |
| (mg AAE/g extract) | ||
| Organic acids profile (mg/g sample) | Oxalic acid | 2.69 ± 0.07 |
| Lactic acid | 1.02 ± 0.22 | |
| Acetic acid | 2.96 ± 0.32 | |
| Citric acid | 31.01 ± 1.40 | |
| Succinic acid | 3.55 ± 0.20 | |
| Kojic acid | 0.04 ± 0.001 | |
| Amino acids (mg/100 g samples) | Alanine | 8.50 ± 0.02 |
| Arginine | 0.65 ± 0.07 | |
| Aspartic acid | 28.00 ± 0.14 | |
| Cysteine | 0.55 ± 0.03 | |
| Glutamic acid | 1.85 ± 0.07 | |
| Glycine | 8.20 ± 0.28 | |
| Proline | 13.25 ± 0.12 | |
| Serine | 0.65 ± 0.02 | |
| Tyrosine | 3.60 ± 0.14 | |
| Asparagine | n.d. | |
| Glutamine | n.d. | |
| Histidine | n.d. | |
| Isoleucine | 5.75 ± 0.71 | |
| Leucine | 6.75 ± 0.02 | |
| Lysine | 0.90 ± 0.14 | |
| Methione | 0.85 ± 0.06 | |
| Phenylalanine | 3.40 ± 0.28 | |
| Threonine | 1.05 ± 0.07 | |
| Tryptophan | n.d. | |
| Valine | 8.35 ± 0.71 | |
| Nonprotein amino acid (mg/100 g samples) | Gamma amino butyric acid (GABA) | 0.50 ± 0.01 |
| Vitamin (μg/100 g samples) | A (β-carotene) | 5050.00 |
| A (Retinol) | n.d. | |
| B1 | n.d. | |
| B2 | n.d. | |
| B3 | n.d. | |
| B5 | n.d. | |
| B6 | n.d. | |
| B7 | n.d. | |
| B9 | 2.20 | |
| C | 13.70 | |
| D2 | n.d. | |
| D3 | 10.60 | |
| E (Alpha-tocopherol) | n.d. | |
| K1 (Phytonadione) | 74.70 |
aNon-essential amino acids (NEAA); bEssential amino acids (EAA); ± standard error; n.d. = not detected
Body weight, organ weight and serum liver enzyme profile of normal and 5 g/kg body weight of Xeniji treated mice for acute toxicity study
| Normal | Xeniji (5 g/kg BW) | |
|---|---|---|
| Day 0 BW (g) | 20.21 ± 1.23 | 22.53 ± 1.29 |
| Day 14 BW (g) | 21.06 ± 0.73 | 23.02 ± 1.86 |
| Liver weight (g) | 1.41 ± 0.09 | 1.59 ± 1.86 |
| Kidney weight (g) | 0.51 ± 0.03 | 0.53 ± 0.04 |
| Spleen weight (g) | 0.14 ± 0.02 | 0.21 ± 0.01 |
| Liver/BW ratio | 0.0517 | 0.0537 |
| Kidney/BW ratio | 0.0187 | 0.0179 |
| Spleen/BW ratio | 0.0049 | 0.0069 |
| ALT (U/L) | 66.83 ± 2.33 | 63.40 ± 3.59 |
| ALP (U/L) | 69.75 ± 3.41 | 75.10 ± 6.77 |
| AST (U/L) | 108.32 ± 3.79 | 112.87 ± 3.41 |
| Creatinine (μmol/L) | 46.00 ± 3.56 | 46.00 ± 2.67 |
No significant different was observed at p < 0.05 and p < 0.001
Body weight, organ weight and serum liver enzyme profile of normal and 5 g/kg body weight of Xeniji treated mice for 30 days of subchronic toxicity study
| Normal | Xeniji 0.1 | Xeniji 1.0 | Xeniji 2.0 | |
|---|---|---|---|---|
| Day 0 BW (g) | 20.42 ± 0.125 | 18.96 ± 0.271 | 19.96 ± 1.297 | 19.67 ± 1.145 |
| Day 28 BW (g) | 24.52 ± 1.370 | 22.91 ± 1.023 | 23.93 ± 1.837 | 23.52 ± 1.116 |
| BW gain (g) | 4.10 ± 1.245 | 3.96 ± 0.752 | 3.97 ± 0.541 | 3.86 ± 0.029 |
| Liver/BW ratio | 0.04 ± 0.005 | 0.04 ± 0.001 | 0.04 ± 0.004 | 0.04 ± 0.009 |
| Kidney/BW ratio | 0.01 ± 0.001 | 0.01 ± 0.001 | 0.01 ± 0.001 | 0.01 ± 0.001 |
| Spleen/BW ratio | 0.003 ± 0.000 | 0.003 ± 0.000 | 0.003 ± 0.000 | 0.003 ± 0.000 |
| Glucose (mmol/L) | 5.50 ± 0.99 | 5.40 ± 0.07 | 5.13 ± 0.76 | 5.00 ± 0.41 |
| ALT (U/L) | 53.68 ± 3.32 | 44.62 ± 1.83*# | 44.33 ± 4.76* | 43.55 ± 2.21*# |
| ALP (U/L) | 72.33 ± 3.84 | 72.67 ± 3.37 | 79.67 ± 4.80 | 78.83 ± 1.89 |
| AST (U/L) | 103.97 ± 4.15 | 108.32 ± 2.10 | 108.04 ± 2.93 | 107.21 ± 5.83 |
| Creatinine (μmol/L) | 43.50 ± 0.40 | 42.00 ± 0.40 | 43.00 ± 0.95 | 42.50 ± 0.21 |
*and #indicates a significant difference compared with the normal control group at p < 0.05 and p < 0.001
Fig. 1Differential expression of (a) GCLM and (b) GSTA2 genes related to Nrf-2 antioxidant pathway on normal and Xeniji (0.1, 1 and 2 g/kg body weight) treated mice. The expression of target genes (±SEM) were normalised to β-actin and the normal group was used as control for comparison. Fold change >2 comparing to normal control group was considered as significant*
Fig. 2a Total antioxidant capacity by quantified FRAP level; b GSH level; c lipid peroxidation MDA level and d NO level in liver of normal and Xeniji (0.1, 1 and 2 g/kg body weight) treated mice. *indicates a significant difference compared with the normal control group, p < 0.05
Fig. 3Differential expression of (a) IL-12 and (b) IL-18 genes in spleen of normal and Xeniji (0.1, 1 and 2 g/kg body weight) treated mice. The expression of target genes (±SEM) were normalised to β-actin and the normal group was used as control for comparison. Fold change >2 comparing to normal control group was considered as significant*
Fig. 4Serum (a) IL-2; (b) IL-12; (c) IL-18 and (d) IFN-γ level in liver of normal and Xeniji (0.1, 1 and 2 g/kg body weight) treated mice. *indicates a significant difference compared with the normal control group, p < 0.05
Fig. 5Immunophenotyping of splenic CD3+CD4+, CD3+CD8+ and CD3+NK1.1+ population by flow cytometer. * indicates a significant difference compared with the normal control group, p < 0.05
Fig. 6Cytotoxicity of splenocytes on YAC-1 cells at ratio 2 to 1. * indicates a significant difference compared with the normal control group, p < 0.05